Uclh sarcoma unit chemotherapy guidelines – bone sarcomas

Sarcoma Advisory Group Chemotherapy Guidelines – Bone Sarcomas
These guidelines include selected trials, generally where these are first line or expected to be open to accrual for some time. Especially for 2nd and 3rd line
treatment, trial options may exist which are not reproduced here but may be the preferred option in individual cases. Where several options exist, then the
choice will be based on individual circumstances, treatment intent, co-morbidity etc and MDT discussion is frequently appropriate.
Sarcoma Type
Category
3rd Line and Other
Clinical trial: GLU-1 glucarpidase study Clinical trial: GLU-1 glucarpidase study VIDE x 6 cycles → VAC or VAI High dose ifosfamid VIDE x 6 cycles → VAC or VAI or
(busulphan/lmelphalan or treosulphan/melphalan) with peripheral blood stem cell rescu N.B. Choice of 2nd line therapy will depend on patient/disease specific factors (e.g. if chemo being given with curative intent) and/or patient choice FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
angiosarcoma, spindle cell sarcoma, dedifferentiated chondrosarcoma Pigmented villonodular Doxorubicin
or
Doxorubicin and cisplatin

* Funding via individual funding request
**Funding via Cancer Drugs Fund (submitted 2012/13)
FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
Sarcoma Advisory Group Chemotherapy Guidelines – Soft Tissue Sarcomas
These guidelines include selected trials, generally where these are first line or expected to be open to accrual for some time. Especially for 2nd and 3rd line
treatment, trial options may exist which are not reproduced here but may be the preferred option in individual cases. Where several options exist, then the
choice will be based on individual circumstances, treatment intent, co-morbidity etc and MDT discussion is frequently appropriate.
Sarcoma Type
Category
3rd Line and Other
N.B. Choice of chemotherapy will depend on disease factors (histiological subtypes) and patient factors (PS, patient choice) Gemcitabine(for poor PS) +/-
docetaxel
or
Aromatase inhibitor (if ER/PR
FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
Vinblastine and methotrexaor Vinorelbine and methotrexa
* Funding via individual funding request
**Funding via Cancer Drugs Fund (submitted 2012/13)
***Funding via Cancer Drugs Fund (approved)


References
1.
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633-8. Epub 2008/02/01. 2. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20(2):426-33. Epub 2002/01/12. 3. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419-25. Epub 2008/05/20. 4. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatric blood & cancer. 2006;47(1):22-9. Epub 2006/03/31. 5. Ferrari S, del Prever AB, Palmerini E, Staals E, Berta M, Balladelli A, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatric blood & cancer. 2009;52(5):581-4. Epub 2009/01/15. 6. Saylors RL, 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463-9. Epub 2001/08/02. FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan- Kettering experience. Pediatric blood & cancer. 2009;53(6):1029-34. Epub 2009/07/29. 8. McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006;17(8):1301-5. Epub 2006/06/20. 9. Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, et al. Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. The oncologist. 2012;17(3):321-e9. 10. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. Journal of pediatric hematology/oncology. 2009;31(10):723-9. Epub 2009/09/04. 11. Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatric blood & cancer. 2004;42(4):320-4. Epub Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284-91. Epub 2010/06/16. 13. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2012;30(33):4148-54. Epub 2012/10/24. 14. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118(6):1649-55. Epub 2011/08/09. 15. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The lancet oncology. 2010;11(3):275-80. Epub 2010/02/13. 16. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. Fleming GF, Heimann PS, Stephens JK, Simon MA, Ferguson MK, Benjamin RS, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer. 1993;72(3):714-8. Epub 1993/08/01. 18. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et al. Response to imatinib plus sirolimus in advanced chordoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009;20(11):1886-94. Epub 2009/07/03. 19. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27(19):3154-60. Epub 2009/05/20. 20. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54. Epub 1997/12/24. 21. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane database of systematic reviews (Online). 2003(3):CD003293. Epub 2003/08/15. 22. van der Graaf WT, Judson, I.R.; Verweig, J. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. . Annals of Oncology. 2012;23(suppl 9). FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer. 2011;47(4):515-9. Epub 2011/01/22. 24. Meazza C, Casanova M, Luksch R, Podda M, Favini F, Cefalo G, et al. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatric blood & cancer. 2010;55(4):617-20. Epub 2010/07/01. 25. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188-96. Epub 2009/08/05. 26. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755-63. Epub 2007/07/03. 27. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86. Epub 2012/05/19. 28. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269-74. Epub 2008/09/24. 29. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44(16):2433-6. Epub 2008/09/06. 30. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104(2):361-6. Epub Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, Michelagnoli M, et al. Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas. Clinical sarcoma research. 2012;2(1):12. Epub 2012/09/25. 32. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939-47. Epub 2011/04/12. 33. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100(3):612-20. Epub 2004/01/28. 34. Meazza C, Bisogno G, Gronchi A, Fiore M, Cecchetto G, Alaggio R, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer. 2010;116(1):233-40. Epub 2009/12/02. 35. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009;45(17):2930-4. Epub 2009/09/22. 36. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92(5):1259-64. Epub 2001/09/26. 37. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. American journal of clinical oncology. Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884-91. Epub 2010/08/21. FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY
Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835-40. Epub 2010/01/06. 40. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Jama. 2012;307(12):1265-72. Epub 2012/03/29. 41. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247-53. Epub 2010/02/04. 42. Demetri GD, Garrett CR, Schoffski P, Shah MH, Verweij J, Leyvraz S, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res. 2012;18(11):3170-9. Epub 2012/06/05. 43. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28(10):1772-9. Epub 2010/03/03. FILE NAME
UCH Sarcoma Unit Chemotherapy Guidelines VERSION NO
AUTHORISED BY

Source: http://www.lsesn.nhs.uk/files/sag-chemotherapy-guidelines.pdf